AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Marksans Pharma Ltd. Capital/Financing Update 2022

Jul 4, 2022

62142_rns_2022-07-04_b0a3a02d-34ca-4e1a-a511-514bc6bb81c6.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

·t· Marksans Pharma Ltd.

4[th] July, 2022

To, BSE Limited Corporate Relation Department PhirozeJeejeeboi Towers, Dalal Street, Mumbai - 400001. Scrip Code: 524404

National Stock Exchange of India Limited Listing Department Exchange Plaza, C-l, Block-G, Bandra-Kurla Complex, Bandra (East), Mumbai -400051. Symbol: MARKSANS

Sub.: Board of Directors of Marksans Pharma Limited ('the Company') to consider the Buyback of Equity Shares Reg.: Intimation under regulation 29(1)(b) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

In terms of Regulation 29(1)(b) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Friday, 8[th] July, 2022 to consider the proposal for buyback of fully paid up equity shares of the Company upto such amount of the aggregate of Company's paid up equity share capital and free reserves as the Board may decide in accordance with the provisions of Section 68, 69 and 70 of the Companies Act, 2013 and the SEBI (Buyback of Securities) Regulations, 2018.

It is further submitted that in terms of the Company's Code of Conduct to Regulate, Monitor and Report Trading by designated persons framed pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended, the trading window for dealing in the shares of the Company for the designated person(s) is already closed w.e.f. July 0 I, 2022 and will remain closed till 48 hours after the declaration of unaudited financial results for the quarter ended June 30, 2022.

Yours Sincerely, For Marksans Pharma Limited

Harshavardhan Panigrahi Company Secretary